GHP Q3 2019

GHP / Q3 2019 25 that science and wisdom are both equally vital to the recovery experience.” The naturalistic, prospective study followed 253 adult patients with opioid use disorder who were admitted to Hazelden Betty Ford’s residential treatment facility in Center City, Minn., between June 2013 and June 2017. The sample population was very high in acuity, with the majority of patients having multiple substance use disorders, multiple co-occurring mental health disorders, and multiple prior treatment episodes. Patients participating in COR- 12 received opioid-specific therapy, education and case management; were given the option of Suboxone, Vivitrol or no medication; and participated in the rest of Hazelden Betty Ford’s treatment model, which utilizes the best-evidence based clinical practices and systematically connects patients to peer support and other recovery resources. Here are some highlights of the findings: Patients had an extremely high level of engagement with COR-12 treatment. Almost all tracked in the study successfully completed residential treatment, and nearly 75 percent stepped down to another program. Such engagement has not been reported elsewhere. Continuous abstinence rates overall were very high at one month and six months, particularly when considering the clinical severity of the patients. Suboxone- and Vivitrol-compliant patients had an abstinence rate over 90 percent at one month, and Vivitrol-compliant patients had a rate of 82 percent at six months. Even patients who chose to use no medications but engaged in COR-12’s opioid-specific therapy, education and case management had an abstinence rate of 74 percent at 6 months. These outcomes are more favorable than those typically reported in research studies. They are also better than Hazelden Betty Ford’s historic data on patients with opioid use disorder, where six-month abstinence rates are typically in the low- to mid-60s. The majority of patients were successfully inducted on medications during residential treatment and many reported complying with the medication schedule during the six-month follow-up period. This suggests a high level of engagement with medications for patients with opioid use disorder, and shows it is feasible to administer medications like Suboxone and Vivitrol within a Twelve Step- oriented environment. As one might suspect, abstinence rates were lower for patients who were noncompliant with their medications—a cue that finding better ways to help patients maintain compliance needs to be a priority. “Our patients with opioid use disorder traditionally did not stay in treatment as long as other patients. The COR-12 results, on the other hand, show an extremely high level of engagement with treatment, validating our hypothesis that patients benefit when given the choice of accessing anti-craving medications as a supplement to their other evidence-based care,” said Val Slaymaker, Ph.D., chief academic officer and provost of the Hazelden Betty Ford Graduate School of Addiction Studies and executive director of Hazelden Betty Ford’s Butler Center for Research. “Length of engagement is important because it helps predict positive outcomes, which is why these results are significant. We will continue to study COR-12 and share the results widely to help inform our own practices and those of the industry.” Jordan Hansen, clinical director of Hazelden Publishing’s Professional Education Solutions, said the rigorously integrated approach of COR-12 is a bridge to a new treatment model for all addictions, not just opioid use disorder. “COR-12 represents a new frontier for addiction treatment and perhaps all of healthcare because it brings the best of medicine, behavioral healthcare and time-tested wisdom traditions together, in an operationalized way, to treat the whole person in an individualized way,” Hansen said. COR-12 has caught the attention of healthcare providers across the country. It was recognized in 2015 by the White House Office of National Drug Control Policy in its annual report to the President, and other providers and health systems nationwide are now turning to the Hazelden Betty Ford Foundation for help implementing a COR-12 framework. “We have introduced COR-12 to a variety of providers—including many federally qualified health centers—in over a dozen states through our training and consultation services,” Hansen said. “The St. Elizabeth hospital system in Kentucky was the first provider outside of the Hazelden Betty Ford Foundation to get training and then deploy COR- 12, and it was able to reverse its the skyrocketing opioid overdose trends, reducing the number it treated from more than 2,000 in 2017 to nearly 1,000 in 2018. “Another partner in Kentucky is the Kenton County Detention Center, which is implementing COR-12 with our help and also collaborating with the University of Kentucky to measure the results and validate that medications can be used safely and effectively in a corrections setting. We hope that it becomes a potential model for the country.” According to the latest official federal statistics, opioids were involved in 47,600 U.S. deaths in 2017, an average of 130 a day and nearly six times the 8,050 opioid overdose deaths recorded in 1999. During those 19 years, opioid overdoses claimed a total of 399,212 lives, with more than 217,000 of those due to prescription opioids. Overdose deaths attributed to fentanyl recorded the sharpest increase in recent years, as it marked 3,105 deaths in 2013 and 27,466 in 2017. Patients with opioid use disorder have unique challenges—like hypersensitivity to pain—that can undermine their ability to remain in treatment and ultimately achieve long-term recovery. It is a population also at great risk of overdose if they relapse on the same doses they were previously taking. COR-12 addresses these challenges by using medications to keep people comfortable enough to stay in treatment and engage in evidence-based clinical therapy and opioid-specific education, and begin connecting to a Twelve Step peer support community. “Because the withdrawal symptoms and physical and psychological draws of opioids persist for so long, keeping patients engaged in treatment became our focus,” said Seppala, the chief medical officer. “Medications help, but we also work hard with patients, their families, and their insurance providers to keep patients engaged in treatment and support services as long as possible. Our ultimate goal is to help patients make the transition from intense clinical management of their diseases to community-supported self- management.” COR-12 was launched in 2012, after Hazelden Betty Ford leaders noted a precipitous rise in opioid addiction among their patient population, and an increase in overdoses post- treatment. “We’ve been mobilizing our entire organization to zero in on the opioid overdose epidemic and broader addiction crisis ever since,” said Mark Mishek, president and CEO. “Adopting medications was a huge cultural shift for our staff, referents, alumni and donors, but it was clearly the right decision. It took some time to operationalize and study COR-12, and we have more research to do. But it’s extremely encouraging to see such positive results from this first research, and I expect we’ll see more. “In a nation plagued by overdose deaths and increasingly overwhelmed by addiction to all manner of substances, we need more hope, more healing, more solutions and more recovery,” Mishek added. “We feel like we’re moving the field forward here, not just in terms of treating opioid use disorder but in terms of treating all addictions. The days of philosophical camps need to be over. It’s time to embrace everything that works, and we’re committed to doing that in a way that is rigorous and replicable.” In Fight to End a Nation’s Opioid Crisis, a New Treatment Approach Emerges